Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
NCT04827745
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
2
Enrollment
OTHER
Sponsor class
Conditions
Mixed Phenotype Acute Leukemia (MPAL)
Measurable Residual Disease (MRD)
Interventions
DRUG:
BLINCYTO (Blinatumomab)
Sponsor
University of Maryland, Baltimore